Skip to main content
logo
Parabilis Medicines, Inc. (PBLS)
NASDAQ: PBLS · Real-Time Price · USD
38.76
+1.54 (4.14%)
Aug 18, 2026, 11:35 AM EDT - Market open

Parabilis Medicines Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-170.53-145.89-117.91
Depreciation & Amortization
2.432.52.11
Loss (Gain) From Sale of Assets
--0.36
Loss (Gain) From Sale of Investments
5.480.61-0.61
Stock-Based Compensation
6.583.324.31
Other Operating Activities
6.896.637.22
Change in Accounts Payable
6.8513.599.28
Change in Other Net Operating Assets
-10.5-4.47-8.37
Operating Cash Flow
-111.29-123.71-103.61
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-1.2-0.31-0.88
Investment in Securities
-24.6740.0631.12
Investing Cash Flow
-25.8739.7630.24

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Long-Term Debt Repaid
--3.08-
Net Debt Issued (Repaid)
-10.61-3.08-
Issuance of Common Stock
802.370.031.07
Other Financing Activities
46.88--0.02
Financing Cash Flow
1,14464.3878.07

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
1,007-19.574.7

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-112.49-124.02-104.49
Free Cash Flow Growth
---
Free Cash Flow Per Share
-11.38-39.83-35.10
Levered Free Cash Flow
--72.4-
Unlevered Free Cash Flow
--71.44-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Cash Interest Paid
1.031.251.03
Change in Working Capital
37.869.120.91
SEC Filings: 10-K · 10-Q